Mitsubishi UFJ Trust & Banking’s NewAmsterdam Pharma NAMS Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147K	Buy	+4,330	New	+$143K	﹤0.01%	1408

Other funds holding NAMS

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's NAMS Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 4,330 shares worth $147K. The stake represents ﹤0.01% of the portfolio and ranks #1408 among its holdings.

66 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 4,330 shares of NewAmsterdam Pharma worth $147K as of Q2 2026.
NewAmsterdam Pharma was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
NewAmsterdam Pharma made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1408 holding.
66 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.